Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts’ perspectives with associated cost-consequence analysis

Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts’ perspectives with associated cost-consequence analysis

Abstract Background Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA) related to congenital mutations impeding control of the alternative pathway of complement. Following approval of the complement C5 inhibitor eculizumab by the European Medicines...

Full description

Saved in:
Bibliographic Details
Main Authors: Evi Germeni, Jacie Cooper, Andrew Briggs, Jeffrey Laurence
Format: Article
Language:English
Published: BMC 2024-11-01
Series:BMC Nephrology
Subjects:
Atypical hemolytic uremic syndrome
Rare diseases
Treatment duration
Qualitative research
Cost-consequence analysis
Online Access:https://doi.org/10.1186/s12882-024-03770-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12882-024-03770-0

Similar Items